Favezelimab/Pembrolizumab

BIOLOGICAL9 trials

Conditions

Carcinoma, Renal CellColorectal CancerCutaneous Squamous Cell CarcinomaEndometrial CancerHodgkin LymphomaMelanomaNeoplasm MetastasisNeoplasms

Phase 1

Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)

CompletedNCT02720068

Merck Sharp & Dohme LLCNeoplasms

Start: 2016-05-02End: 2024-03-15Updated: 2025-05-30

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

Active, not recruitingNCT04305054

Merck Sharp & Dohme LLCMelanoma

Start: 2020-07-01End: 2026-04-20Target: 315Updated: 2025-08-29

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

Active, not recruitingNCT04626518

Merck Sharp & Dohme LLCCarcinoma, Renal Cell

Start: 2020-12-17End: 2026-05-31Target: 370Updated: 2025-07-25

Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

Active, not recruitingNCT04626479

Merck Sharp & Dohme LLCCarcinoma, Renal Cell

Start: 2020-12-16End: 2026-05-31Target: 400Updated: 2026-02-12

A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)

WithdrawnNCT06395090

Merck Sharp & Dohme LLCNeoplasm Metastasis

Start: 2025-01-15End: 2029-06-30Updated: 2025-04-08

Phase 2

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

CompletedNCT05508867

Merck Sharp & Dohme LLCHodgkin Lymphoma

Start: 2022-10-18End: 2026-01-08Updated: 2026-01-20

Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

CompletedNCT06036836

Merck Sharp & Dohme LLCCutaneous Squamous Cell Carcinoma, Endometrial Cancer, Solid Tumor

Start: 2023-09-29End: 2026-03-12Updated: 2026-03-19

Phase 3

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

CompletedNCT05064059

Merck Sharp & Dohme LLCColorectal Cancer

Start: 2021-11-10End: 2025-02-21Updated: 2025-09-17

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

CompletedNCT05600309

Merck Sharp & Dohme LLCColorectal Cancer

Start: 2022-06-14End: 2025-02-21Updated: 2025-11-26

2025-10-183 citations

CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours.

2025-02-271 citations

KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and targeted therapy combinations for advanced clear cell renal cell carcinoma (ccRCC).

Journal of Clinical Oncology2025-02-102 citations

KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and novel immunotherapy agents for advanced clear cell renal cell carcinoma (ccRCC).

Journal of Clinical Oncology2025-02-101 citations

Co-formulated favezelimab plus pembrolizumab versus standard-of-care in previously treated, PD-L1-positive metastatic colorectal cancer: The phase 3, randomized KEYFORM-007 study.

Journal of Clinical Oncology2025-01-272 citations

Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study

Journal of Clinical Oncology2024-06-0455 citations

A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti–PD-1–refractory classical Hodgkin lymphoma (cHL): An updated analysis.

Journal of Clinical Oncology2024-06-011 citations

308 A randomized, double-blind, phase 2 study of MK-4280A (coformulation of favezelimab and pembrolizumab) plus lenvatinib vs pembrolizumab plus lenvatinib in patients with previously treated mismatch repair-proficient advanced endometrial cancer

2024-03-01

Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

Blood2023-11-024 citations

Open-Label, Randomized, Phase 3 Study of Coformulated Favezelimab and Pembrolizumab Versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Therapy: Keyform-008

Blood2023-11-022 citations

3 External reproducibility of PD-L1 IHC 22C3 pharmDx for colorectal carcinoma specimens at CPS ≥ 1 cutoff

Regular and Young Investigator Award Abstracts2023-10-31

Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.

2023-08-075 citations

Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study.

Journal of Clinical Oncology2023-06-0110 citations

KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.

Journal of Clinical Oncology2023-06-013 citations

Neoadjuvant & Adjuvant Therapy Using Pembrolizumab for Melanoma

Oncology Times2023-04-19

Phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer.

Journal of Clinical Oncology2023-01-249 citations

Phase 1b/2 umbrella study of investigational immune and targeted combination therapies for patients with advanced clear cell renal cell carcinoma (ccRCC).

Journal of Clinical Oncology2022-02-161 citations

Abstract CT243: A phase 1b/2 umbrella study of investigational immune and targeted combination therapies for patients with advanced renal cell carcinoma (RCC) who progressed on PD-1/L1 and VEGF inhibitors

Cancer Research2021-07-01

A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.

Journal of Clinical Oncology2021-05-2046 citations

A phase 1b/2 umbrella study of investigational immune and targeted combination therapies as first-line therapy for patients with advanced renal cell carcinoma (RCC).

Journal of Clinical Oncology2021-05-206 citations

1 more papers not shown

Favezelimab/Pembrolizumab

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Related Papers